Health care stocks fall as lawmakers, patients push for changes to their business models

Health care stocks fall as lawmakers, patients push for changes to their business models


UnitedHealth Group signage is displayed on a monitor on the floor of the New York Stock Exchange.

Michael Nagle | Bloomberg | Getty Images

Shares of major health-care companies fell as much as 5% on Wednesday as investors feared pressure from lawmakers and patients could force changes to their business models.

The declining stocks include UnitedHealth Group, Cigna and CVS Health, which operate three of the nation’s largest private health insurers and drug supply chain middlemen called pharmacy benefit managers, or PBMs. They also own pharmacy businesses. Shares of all three companies were down at least 4.8% in early afternoon trading.

The stock reaction on Wednesday appeared to be in response to new bipartisan legislation that aims to break up PBMs, which was first reported by the Wall Street Journal. PBMs have faced years-long scrutiny from Congress and the Federal Trade Commission over allegations they inflate drug costs for patients to boost their profits. 

The share moves also come as insurance companies and their practices face heightened public criticism following the fatal shooting of Brian Thompson, the CEO of UnitedHealth Group’s insurance arm, last week. Health stocks had already fallen in the days after Thompson’s killing.

A Senate bill, sponsored by Sens. Elizabeth Warren,  D-Mass., and Josh Hawley, R-Mo., would force the companies that own health insurers or PBMs to divest their pharmacy businesses within three years, the Journal reported. The lawmakers told the Journal that a companion bill is scheduled to be introduced in the House on Wednesday.

“PBMs have manipulated the market to enrich themselves—hiking up drug costs, cheating employers, and driving small pharmacies out of business,” Warren said in a release. “My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen.”

The release added that healthcare companies that own both PBMs and pharmacies are a “gross conflict of interest that enables these companies to enrich themselves at the expense of patients and independent pharmacies.”

The largest PBMs – UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts – are all owned by or connected to health insurers. They collectively administer about 80% of the nation’s prescriptions, according to the FTC.

PBMs sit at the center of the drug supply chain in the U.S., negotiating rebates with drug manufacturers on behalf of insurers, large employers and federal health plans. They also create lists of medications, or formularies, that are covered by insurance and reimburse pharmacies for prescriptions.

The FTC has been investigating PBMs since 2022. 

— CNBC’s Bertha Coombs contributed to this report



Source

Congressional hemp restrictions threaten  billion industry, sending companies scrambling
Health

Congressional hemp restrictions threaten $28 billion industry, sending companies scrambling

The hemp industry is bracing for layoffs, production reductions and billions in lost revenue after Congress passed a government funding bill late Wednesday containing a surprise provision that will ban nearly all hemp-derived consumer products. Hemp, a derivative of the cannabis plant, was legalized in the 2018 Farm Bill for industrial uses like rope, textiles […]

Read More
Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal
Health

Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal

Every step is a struggle for Bruce Zimmerman, whose health has been deteriorating since he was diagnosed with multiple sclerosis eight years ago. In 2019, Zimmerman said, his then-employer offered him an opportunity that sounded irresistible: He and his wife, Becky, could take all-expense-paid trips to the Cayman Islands and the Bahamas to retrieve the medication […]

Read More
Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data
Health

Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data

A view shows a Novo Nordisk sign outside its office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. All […]

Read More